F Devotta1, C Beck2

1Hospital of the University of Pennsylvania, Philadelphia PA.

2Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia PA.

Peripheral neuropathy in the trastuzumab and non trastuzumab groups will be evaluated to see if there is a marked difference in neuropathy incidence at the end of taxane treatment. Additionally, paclitaxel and docetaxel groups will be compared to see if there are any neuropathy score differences. Charts of breast cancer patients who received paclitaxel or docetaxel as adjuvant or neoadjuvant chemotherapy between 2010 and 2012 as part of the Cardiotoxicity of Cancer Therapy (CCT) study were retrospectively analyzed via case report forms. AC+T: There were 23 patients who showed no difference in neuropathy scores post taxane when compared to baseline. This was the highest number of patients with no difference in neuropathy when comparing baseline and the last visit. T+AC: Analysis of neuropathy in 16 patients revealed that only four of those patients reported neuropathy at study visits during taxane therapy. AC+TH: Nine out 15 patients had no symptoms of neuropathy when the baseline and the end of taxane therapy.

TH+AC: There were only five patients in this group and two experienced no symptoms at the end of taxane therapy. TCyH: There were a total of 10 patients and four patients had no symptoms at baseline through the end of taxane therapy. TCH: Four patients out of nine patients reported no symptoms at all during the course of the study. In comparing trastuzumab versus non trastuzumab neuropathy, the non trastuzumab group did have a higher incidence of neuropathy at the end of taxane treatment than the trastuzumab group (59% non-trastuzumab n=86 vs. 51% trastuzumab) n=39). The percentage of incidence of neuropathy in both paclitaxel and docetaxel groups were very close (paclitaxel 57% n=106 vs. docetaxel 58% n=19).